Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
grade F 18.85 -2.33% -0.45
BYSI closed down 2.33 percent on Friday, January 18, 2019, on 26 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BYSI trend table...

Date Alert Name Type % Chg
Jan 18 Fell Below 20 DMA Bearish 0.00%
Jan 18 Bollinger Band Squeeze Range Contraction 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 17 20 DMA Support Bullish -2.33%
Jan 17 Pocket Pivot Bullish Swing Setup -2.33%
Jan 17 Bollinger Band Squeeze Range Contraction -2.33%
Jan 17 BB Squeeze + Upper Band Touch Range Contraction -2.33%
Jan 17 Outside Day Range Expansion -2.33%
Jan 17 Upper Bollinger Band Touch Strength -2.33%

Older signals for BYSI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Is BYSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.0
52 Week Low 16.15
Average Volume 7,599
200-Day Moving Average 24.0978
50-Day Moving Average 20.6551
20-Day Moving Average 18.8837
10-Day Moving Average 18.997
Average True Range 0.9005
ADX 16.24
+DI 25.1699
-DI 23.3749
Chandelier Exit (Long, 3 ATRs ) 18.4585
Chandelier Exit (Short, 3 ATRs ) 19.8915
Upper Bollinger Band 19.6239
Lower Bollinger Band 18.1435
Percent B (%b) 0.48
BandWidth 7.839565
MACD Line -0.4807
MACD Signal Line -0.6113
MACD Histogram 0.1306
Fundamentals Value
Market Cap 430.61 Million
Num Shares 22.8 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -5.08
Price-to-Sales 0.00
Price-to-Book 16.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.30
Resistance 3 (R3) 19.35 19.25 19.23
Resistance 2 (R2) 19.25 19.14 19.23 19.20
Resistance 1 (R1) 19.05 19.06 19.00 19.00 19.17
Pivot Point 18.95 18.95 18.93 18.93 18.95
Support 1 (S1) 18.75 18.84 18.70 18.70 18.53
Support 2 (S2) 18.65 18.76 18.63 18.50
Support 3 (S3) 18.45 18.65 18.48
Support 4 (S4) 18.40